N-[4-(aminomethyl)phenyl]-N-methylmethanesulfonamide | 1018519-22-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-(aminomethyl)phenyl]-N-methylmethanesulfonamide
• CAS: 1018519-22-6
• 化学式: C₉H₁₄N₂O₂S
• mdl: MFCD10025581
• 分子量: 214.288
• InChiKey: XWCLCOIBKJCXIK-UHFFFAOYSA-N

物化性质

• 沸点：
  369.8±44.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-叔-丁基苄基异硫氰酸酯 、 N-[4-(aminomethyl)phenyl]-N-methylmethanesulfonamide 以 二氯甲烷 为溶剂， 生成 1-[(4-Tert-butylphenyl)methyl]-3-[[4-[methyl(methylsulfonyl)amino]phenyl]methyl]thiourea
  参考文献：
  名称：

  N-4-Substituted-benzyl-N′-tert-butylbenzyl thioureas as vanilloid receptor ligands: investigation on the role of methanesulfonamido group in antagonistic activity

  摘要：

  A series of N-4-substituted-benzyl-N'-tert-butylbenzyl thioureas were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor in rat DRG neurons. Their structure-activity relationship reveals that not only the two oxygens and amide hydrogen of sulfonamido group, but also the optimal size of methyl in methanesulfonamido group play an integral role for the antagonistic activity on vanilloid receptor. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.019
• 作为产物：
  描述：

  tert-butyl N-[[4-(methanesulfonamido)phenyl]methyl]carbamate 在 sodium hydride 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 N-[4-(aminomethyl)phenyl]-N-methylmethanesulfonamide
  参考文献：
  名称：

  N-4-Substituted-benzyl-N′-tert-butylbenzyl thioureas as vanilloid receptor ligands: investigation on the role of methanesulfonamido group in antagonistic activity

  摘要：

  A series of N-4-substituted-benzyl-N'-tert-butylbenzyl thioureas were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor in rat DRG neurons. Their structure-activity relationship reveals that not only the two oxygens and amide hydrogen of sulfonamido group, but also the optimal size of methyl in methanesulfonamido group play an integral role for the antagonistic activity on vanilloid receptor. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.019

文献信息

• [EN] 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS<br/>[FR] COMPOSES 1H-PYRAZOLE 3,4-DISUBSTITUES ET LEUR UTILISATION EN TANT QUE KINASES DEPENDANT DES CYCLINES (CDK) ET MODULATEURS DE LA GLYCOGENE SYNTHASE KINASE-3 (GSK-3)
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005012256A1

  公开（公告）日：2005-02-10

  The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. Formula (0). In formula (0): X is a group R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, S02, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from 0, S, NH, SO, S02; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).

  该发明提供了以下式（0）的化合物或其盐或互变异构体或N-氧化物或其溶剂合物，用于预防或治疗由细胞周期依赖性激酶和糖原合成酶-3介导的癌症等疾病状态和病症。在式（0）中：X是一个基团R1-A-NR4-或一个5-或6-成员的碳环或杂环；A是一个键，S02，C=O，NRg（C=O）或O（C=O），其中Rg是氢或C1-4烃基，可以选择性地被羟基或C1-4烷氧基取代；Y是一个键或一个由1、2或3个碳原子组成的烷基链；R1是氢；一个具有3到12个环成员的碳环或杂环基团；或一个C1-8烃基，可以选择性地被卤素（如氟）、羟基、C1-4烷氧基、氨基、单或双C1-4烃基氨基以及具有3到12个环成员的碳环或杂环基团取代，其中烃基的1或2个碳原子可以选择性地被从0、S、NH、SO、S02中选择的原子或基团所取代；R2是氢；卤素；C1-4烷氧基（如甲氧基）；或一个C1-4烃基，可以选择性地被卤素（如氟）、羟基或C1-4烷氧基（如甲氧基）取代；R3从氢和具有3到12个环成员的碳环或杂环基团中选择；R4是氢或一个C1-4烃基，可以选择性地被卤素（如氟）、羟基或C1-4烷氧基（如甲氧基）取代。
• Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
  申请人：Curry Jayne Elizabeth

  公开号：US20080161355A1

  公开（公告）日：2008-07-03

  The invention provides a combination of a compound having the formula (0) and two or more further anti-cancer agents: or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R 1 -A-NR 4 — or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C═O, NR 9 (C═O) or 0(C═O) wherein R 9 is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R 1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C 1-4 hydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; R 2 is hydrogen; halogen; C 1-4 alkoxy (e.g. methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy); R 3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R 4 is hydrogen or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy).

  本发明提供了一种由具有公式（0）的化合物和两种或更多进一步的抗癌剂组成的组合物：或其盐或互变异构体或N-氧化物或溶剂化物；其中X是一个R1-A-NR4-或一个5-或6-成员的碳环或杂环环；A是一个键，SO2，C═O，NR9（C═O）或0（C═O），其中R9是氢或C1-4烃基，可以选择地被羟基或C1-4烷氧基取代；Y是一个键或长度为1、2或3个碳原子的烷基链；R1是氢；具有3到12个环成员的碳环或杂环基团；或者是一个C1-8烃基，可以选择地被一个或多个取代基所取代，所述取代基选自卤素（例如氟）、羟基、C1-4烃氧基、氨基、单-或双C1-4烃基氨基和具有从3到12个环成员的碳环或杂环基团，其中烃基的1或2个碳原子可以选择性地被O、S、NH、SO、SO2中的一个原子或基取代；R2是氢；卤素；C1-4烷氧基（例如甲氧基）；或一个C1-4烃基，可以选择地被卤素（例如氟）、羟基或C1-4烷氧基（例如甲氧基）所取代；R3选自氢和具有从3到12个环成员的碳环和杂环基团；R4是氢或一个C1-4烃基，可以选择地被卤素（例如氟）、羟基或C1-4烷氧基（例如甲氧基）所取代。
• Pharmaceutical Compounds
  申请人：Curry Jayne Elizabeth

  公开号：US20080161251A1

  公开（公告）日：2008-07-03

  The invention provides a combination of a cytotoxic compound or signalling inhibitor and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R 1 -A-NR 4 - or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO 2 , C═O, NR g (C═O) or 0(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R 1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C 1-4 hydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; R 2 is hydrogen; halogen; C 1-4 alkoxy (e.g. methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy); R 3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R 4 is hydrogen or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy).

  本发明提供了一种细胞毒性化合物或信号抑制剂与式(0)的化合物或其盐、互变异构体、N-氧化物或溶剂化物的组合物；其中X是一个R1-A-NR4-或5-或6-成员的碳环或杂环；A是一个键，SO2，C═O，NRg(C═O)或0(C═O)，其中Rg是氢或C1-4羟基或C1-4烷氧基取代的烷基；Y是一个键或1、2或3个碳原子长的烷基链；R1是氢；一个从3到12个环成员的碳环或杂环基团；或一个C1-8烷基基团，可选地取代一个或多个取代基，所述取代基选自卤素（例如氟）、羟基、C1-4烷氧基、氨基、C1-4单取代或双取代烷基氨基和从3到12个环成员的碳环或杂环基团，其中烷基基团的1或2个碳原子可以选为O、S、NH、SO或SO2中的原子或基团；R2是氢；卤素；C1-4烷氧基（例如甲氧基）；或一个C1-4烷基基团，可选地取代卤素（例如氟）、羟基或C1-4烷氧基（例如甲氧基）；R3选自氢和从3到12个环成员的碳环或杂环基团；R4是氢或一个C1-4烷基基团，可选地取代卤素（例如氟）、羟基或C1-4烷氧基（例如甲氧基）。
• 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
  申请人：Berdini Valerio

  公开号：US20060194843A1

  公开（公告）日：2006-08-31

  The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. In formula (0): X is a group R 1 -A-NR 4 — or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO 2 , C═O, NR g (C═O) or O(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R 1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C 1-4 hydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; R 2 is hydrogen; halogen; C 1-4 alkoxy (e.g. methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy); R 3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R 4 is hydrogen or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy).

  本发明提供了公式（0）的化合物或其盐或互变异构体或N-氧化物或其溶剂化物，用于预防或治疗由细胞周期依赖性激酶和糖原合成酶激酶3介导的癌症等疾病状态和病症。在公式（0）中：X是R1-A-NR4-基团或5或6元环烷基或杂环烷基；A是键，SO2，C═O，NRg（C═O）或O（C═O），其中Rg是氢或C1-4烃基，可选地被羟基或C1-4烷氧基取代；Y是键或1、2或3个碳原子长的烷基链；R1是氢；具有3到12个环成员的碳环或杂环基团；或C1-8烃基，可选地被一个或多个取代基选自卤素（例如氟）、羟基、C1-4烃氧基、氨基、单或双C1-4烃基氨基和具有3到12个环成员的碳环或杂环基团取代；其中烃基的1或2个碳原子可选地被O、S、NH、SO、SO2中选取的原子或基团所取代；R2是氢、卤素、C1-4烷氧基（例如甲氧基）或C1-4烃基，可选地被卤素（例如氟）、羟基或C1-4烷氧基（例如甲氧基）取代；R3选自氢和具有3到12个环成员的碳环或杂环基团；R4是氢或C1-4烃基，可选地被卤素（例如氟）、羟基或C1-4烷氧基（例如甲氧基）取代。
• PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
  申请人：Bondy Steven S.

  公开号：US20080182870A1

  公开（公告）日：2008-07-31

  Pyrido(3,2-d)pyrimidine derivatives represented by the structural formula (I): wherein: R 4 is hydrogen, and R 1 , R 2 and R 3 together provide a specific substitution pattern, pharmaceutical acceptable addition salts, stereochemical isomeric forms, N-oxides, solvates and pro-drugs thereof, are useful in the treatment of hepatitis C.

  结构式（I）所代表的吡啶并（3,2-d）嘧啶衍生物：其中：R4为氢，且R1、R2和R3共同提供一种特定的取代模式，其药用可接受的加盐物、立体化学异构体形式、N-氧化物、溶剂合物和前药，可用于治疗丙型肝炎。